stockportfolio.pro
Stocks / BLCO vs CGON
BLCO vs CGON
Bausch + Lomb Corporation and CG Oncology, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Bausch + Lomb Corporation (BLCO) | CG Oncology, Inc. (CGON) | |
|---|---|---|
| Market cap | $5.4B | $5.1B |
| Revenue (latest FY) | $5.10B | $4.04M |
| Net income (latest FY) | $-360.00M | $-161.00M |
| Revenue growth (5y CAGR) | 8.4% | 176.6% |
| Net margin | -7.1% | -3985.0% |
| Return on equity | -5.6% | -21.4% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BLCO — free Open CGON — freeFrequently asked questions
Which is bigger, BLCO or CGON?
Bausch + Lomb Corporation is larger by market capitalization — $5.4B versus $5.1B.
Which grows faster, BLCO or CGON?
Over the last five fiscal years, CG Oncology, Inc. grew revenue faster — 176.6%/yr versus 8.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.